Global Blood Plasma Fractionation Market Strategic Research Report

Scope of the Report

The global Blood Plasma Fractionation market size is predicted to grow from US$ 35,510 million in 2025 to US$ 57,920 million in 2032; it is expected to grow at a CAGR of 7.3% from 2026 to 2032.

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation. In this report, we mainly study the Blood Plasma Fractionation products, such as: Immune Globulin, Coagulation Factor, Albumin, etc.

Market Drivers:

Increasing Demand for Plasma-Derived Therapies: The rising prevalence of chronic diseases, such as immune deficiencies, hemophilia, and autoimmune disorders, has led to increased demand for plasma-derived products like immunoglobulins, clotting factors, and albumin, driving the blood plasma fractionation market.

Aging Population: The global aging population is more prone to chronic diseases and conditions requiring plasma-derived therapies, contributing to the growth of the plasma fractionation market.

Growing Use of Immunoglobulins: Immunoglobulins are increasingly used in the treatment of a wide range of diseases, including primary and secondary immune deficiencies, boosting the need for blood plasma fractionation to produce these therapies.

Rising Healthcare Expenditure and Improved Healthcare Access: Expanding healthcare infrastructure in developing countries, combined with rising healthcare expenditure, is driving demand for advanced medical treatments and plasma-derived products.

Market Challenges:

High Costs of Plasma-Derived Products: The complex and time-consuming process of plasma fractionation leads to high costs for plasma-derived products, making these treatments less accessible, particularly in low-income regions.

Limited Plasma Supply: The availability of plasma for fractionation is often limited by low donation rates, regulatory restrictions, and the lengthy process of screening and collecting plasma, leading to supply shortages.

Stringent Regulatory Framework: Plasma fractionation is subject to rigorous regulatory requirements to ensure safety and efficacy. Meeting these regulations can increase development costs and slow the introduction of new products to the market.

Complex Manufacturing Process: The plasma fractionation process is technically challenging and requires significant investment in infrastructure, equipment, and skilled labor, posing barriers for new entrants and smaller manufacturers.

The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.

The classification of Blood Plasma Fractionation includes Immune Globulin, Coagulation Factor, Albumin and Other. In 2023, Immune Globulin accounted for a share of 51% in the global Blood Plasma Fractionation market.

North America is the largest consumption place, with a revenue market share nearly 40 % in 2023. Following North America, Europe is the second largest consumption place with the revenue market share of 24 %; China is also an important sales region for the Blood Plasma Fractionation.

This report presents a comprehensive overview of the global Blood Plasma Fractionation market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Immune Globulin
• Coagulation Factor
• Albumin
• Other

Segment by players, this report covers

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• RAAS
• CBPO
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio
• Nanyue Bio
• KM Biologics

Segment by Application

• Hospital
• Retail Pharmacy
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Plasma Fractionation market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Retail Pharmacy, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact